Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease

Conclusion: Finerenone contributes to the reduction of UACR and can ameliorate the deterioration of renal function in patients with T2D and CKD. The higher risk of hyperkalemia was found in the finerenone group compared with placebo, however, there was no difference in the risk of overall adverse events.
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research